Contributors: Oyagüez,I Pharmacoeconomics and Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, Spain. Gómez-Peralta,F Unidad de Endocrinología y Nutrición, Hospital General de Segovia, Segovia, Spain. Artola,S Centro de Salud José Marvá, Madrid, Spain. Carrasco,FJ UGC Medicina Interna, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain. Carretero-Gómez,J Servicio de Medicina Interna, Hospital de Zafra, Badajoz, Spain. García-Soidan,J García-Soidan Porriño Primary Care Centre, Pontevedra, Spain. Gómez-Huelgas,R Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga; and Ciber Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. Merino-Torres,JF Endocrinología y Nutrición, Departamento Medicina, Hospital Universitario y Politécnico La Fe, Universitat de Valencia, Valencia, Spain. Pérez,A Servicio de Endocrinología y Nutrición. Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, CIBERDEM, Universitat Autónoma de Barcelona, Barcelona, Spain.; Abbott Diabetes Care provided unconditional financial support to performing the analysis, medical writing and the journal’s Rapid Service Fee.
نبذة مختصرة : Introduction: FreeStyle Libre 2 system is a sensor-based flash-monitoring system that measures interstitial fluid glucose. The study aimed to compare cost of FreeStyle Libre 2 system and self monitoring of blood glucose (SMBG) in the type 2 diabetes mellitus (T2DM) population from the Spanish Health System perspective. Methods: On the basis of data collected from a literature review, the cost of glucose monitoring was modelled for patients with T2DM on a basal-bolus insulin regimen. The cost estimate included annual consumption for glucose monitoring (strips, lancets and sensors) and severe hypoglycaemic events (SHE) manage ment. A published rate of SHE (2.5 episodes/patient-year) was considered. A reduction of SHE (- 48.8%) associated with FreeStyle Libre 2 system, derived from the REPLACE trial, was applied. Hospital attendance for 20.5% of SHEs (with subsequent hospital ization in 16.0%) was applied. Consumption of strips and lancets was set at 6/day for SMBG (derived from national monitoring recommendations), and 0.2/day for FreeStyle Libre 2 sys tem users, with 26 FreeStyle Libre 2 sensors/ year. Unitary costs (€, year 2020 excluding VAT) were derived from literature (€0.28/strip; €0.09/ lancet; €3.09/daily FM sensor; €3804/hospital ized SHE; €1794/hospital-attended non-admit ted SHE; €389/community-attended SHE). Results: Costs were €2700 and €2120/year/pa tient using SMBG or FreeStyle Libre 2 system, respectively. For 1000 patients with T2DM using basal-bolus insulin, 1220 SHEs/year (with 48 hospitalizations) could be prevented and FreeSytle Libre 2 system could generate cost savings of up to €580,953/year versus SMBG (- 21.5%) Conclusion: FreeStyle Libre 2 system is a potential cost-saving strategy in patients with T2DM in Spain on a basal-bolus insulin regimen. ; Yes
Processing Request
No Comments.